Osteoarthritis is the most prevalent joint disease in the world and the leading musculoskeletal cause of disability in older adults, affecting an estimated five hundred million people globally and representing one of the most significant contributors to pain, functional limitation, and reduced quality of life across all demographic groups. For much of its clinical history, osteoarthritis was understood primarily as an inevitable consequence of aging and mechanical wear, a condition in which the articular cartilage covering the ends of bones simply wore away over decades of use, leading to the bone-on-bone contact, joint space narrowing, and pain visible on plain radiographs. This reductive mechanical model, while capturing an important element of osteoarthritis pathology, has been substantially revised and enriched by three decades of advancing basic and clinical science that has revealed osteoarthritis as a complex, multifactorial disease involving not only cartilage but the entire joint organ, including subchondral bone, synovium, ligaments, and periarticular muscles, and driven by an interplay of mechanical, biological, and systemic factors far more sophisticated than simple wear and tear.
Understanding the true nature of osteoarthritis, its risk factors, its diverse clinical presentations, and the growing range of evidence-based management strategies available for its treatment is essential for clinicians across multiple specialties and for the patients who live with this condition every day. Osteoarthritis is not simply a disease of older age that must be endured until joint replacement is offered. It is a condition whose progression can be meaningfully influenced by weight management, exercise, pharmacological analgesia, joint protection strategies, and emerging disease-modifying approaches, and whose pain burden can be substantially reduced through appropriately targeted treatment even when the underlying structural changes cannot be reversed.
Pathological Mechanisms of Cartilage Degradation
Articular cartilage is a highly specialized tissue designed to distribute mechanical loads across the joint surface, provide a nearly frictionless bearing surface for joint movement, and resist the compressive forces of weight-bearing without fatigue over a lifetime. These mechanical properties depend on the precise molecular architecture of the cartilage extracellular matrix, primarily composed of type II collagen fibers that provide tensile strength and a highly hydrated proteoglycan gel, principally aggrecan, that provides compressive stiffness by trapping water within the matrix. The chondrocytes embedded within this matrix are responsible for maintaining the balance between extracellular matrix synthesis and degradation that preserves cartilage structural integrity throughout life.
Osteoarthritis develops when this homeostatic balance is disrupted, with catabolic processes exceeding anabolic repair capacity in a progressive and ultimately irreversible process of cartilage matrix degradation. The initiating events vary between individuals and reflect the diverse risk factors for osteoarthritis: excessive mechanical loading from obesity or malalignment concentrating stress on vulnerable cartilage regions, prior joint injury that disrupts the normal distribution of forces across the articular surface, age-related decline in chondrocyte mitochondrial function that reduces cellular energy available for matrix synthesis, and genetic variation in the genes encoding cartilage matrix proteins or their regulatory pathways that predisposes certain individuals to more rapid cartilage breakdown under equivalent mechanical conditions.
Once initiated, the cartilage degradation process is amplified by a cascade of inflammatory mediators that convert osteoarthritis from a purely mechanical to a biologically driven disease. Damaged chondrocytes and activated synoviocytes release interleukin-1 beta and tumor necrosis factor alpha, cytokines that suppress proteoglycan synthesis by chondrocytes while simultaneously promoting the production of matrix-degrading enzymes including matrix metalloproteinases and aggrecanases. These enzymes cleave the collagen and aggrecan components of the cartilage matrix, releasing degradation fragments that further activate synovial inflammation, creating a self-amplifying cycle of cartilage loss and synovial inflammatory response. The subchondral bone beneath the degrading cartilage undergoes concurrent remodeling, with areas of increased bone density forming beneath cartilage-denuded regions and cystic changes developing from elevated local mechanical stress, producing the radiographic hallmarks of established osteoarthritis.
Risk Factors and Clinical Presentations
The risk factors for osteoarthritis are multiple and interactive, encompassing both systemic factors that increase overall susceptibility and local factors that determine which specific joints are affected. Age is the most powerful systemic risk factor, reflecting the cumulative effect of decades of mechanical loading on cartilage with progressively declining regenerative capacity, the age-related increase in systemic low-grade inflammation, and the mitochondrial dysfunction of aging chondrocytes that impairs their response to mechanical and inflammatory stress. Obesity is a major modifiable risk factor for knee and hip osteoarthritis through both mechanical mechanisms, as each kilogram of excess body weight generates approximately four kilograms of additional compressive force on the knee during walking, and metabolic mechanisms, as adipose tissue releases adipokines including leptin and resistin that directly promote chondrocyte catabolism and synovial inflammation even in non-weight-bearing joints such as the hands.
Female sex confers significantly elevated osteoarthritis risk, particularly following menopause, a pattern that implicates estrogen in the protection of articular cartilage biology during the reproductive years and its loss as a contributor to accelerated cartilage degradation in the post-menopausal period. Prior joint injury, including anterior cruciate ligament tears, meniscal injuries, and intraarticular fractures, dramatically increases the risk of post-traumatic osteoarthritis in the affected joint, with studies documenting rates of radiographic osteoarthritis at ten to twenty years following anterior cruciate ligament injury that approach seventy percent or higher. Joint malalignment, including varus or valgus deformity of the knee and hip dysplasia, concentrates mechanical loading on the medial or lateral compartment of the joint and accelerates localized cartilage loss in the overloaded region.
The clinical presentation of osteoarthritis is remarkably variable, reflecting the diverse joints that can be affected, the different structural changes that predominate in different individuals, and the complex relationship between structural joint changes and pain that means radiographic severity and pain severity frequently do not correspond closely. Pain in osteoarthritis characteristically worsens with activity and mechanical loading of the affected joint and improves with rest, distinguishing it from the inflammatory joint pain of rheumatoid arthritis that is typically worst with inactivity and improves with movement. Morning stiffness in osteoarthritis is present but brief, typically lasting less than thirty minutes, compared to the prolonged morning stiffness of at least one hour that characterizes inflammatory arthritis. Crepitus, the audible or palpable grating sensation during joint movement produced by irregularities in the articular surfaces, is a characteristic feature of osteoarthritis and is often distressing to patients even when it is not directly painful.
Evidence-Based Treatment Approaches
The management of osteoarthritis encompasses a spectrum of non-pharmacological, pharmacological, and procedural interventions whose selection and combination should be individualized based on the specific joints affected, the severity of symptoms, the patient’s overall health status and comorbidities, and their personal treatment goals and preferences. Non-pharmacological interventions, particularly land-based and aquatic exercise programs and weight management for overweight and obese patients, have the strongest evidence base and the most favorable long-term benefit-to-risk ratios of any osteoarthritis treatment and should be foundational components of management for virtually all patients.
Pharmacological management of osteoarthritis pain begins with topical NSAIDs, particularly topical diclofenac, which provide locally delivered anti-inflammatory analgesia with minimal systemic absorption and adverse effects, making them appropriate first-line agents particularly for knee and hand osteoarthritis. Oral NSAIDs provide superior analgesia to acetaminophen for osteoarthritis pain based on meta-analytic evidence and are appropriate for patients without significant cardiovascular, gastrointestinal, or renal contraindications. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, has emerged as an important non-opioid analgesic option for osteoarthritis, with randomized controlled trial evidence demonstrating meaningful pain reduction through its enhancement of descending pain inhibitory pathways, providing an option specifically targeting the central sensitization component of osteoarthritis pain.
Intraarticular corticosteroid injections provide short-term pain relief in knee osteoarthritis through their suppression of synovial inflammation and are appropriate for patients with clinical evidence of joint effusion and inflammatory flare. The analgesic benefit typically lasts four to eight weeks, and repeated injections at intervals of three months or longer are generally considered safe. Surgical management, centering on total joint arthroplasty for end-stage osteoarthritis of the hip and knee, remains one of the most cost-effective interventions in all of medicine for appropriately selected patients, providing durable pain relief and functional restoration that substantially improve quality of life and that cannot be achieved through non-surgical means in severe disease.